S&P 500   3,281.06 (-1.16%)
DOW   27,147.70 (-1.84%)
QQQ   266.56 (-0.12%)
AAPL   109.36 (+2.36%)
MSFT   201.74 (+0.67%)
FB   248.50 (-1.60%)
GOOGL   1,424.16 (-1.86%)
AMZN   2,942.44 (-0.42%)
NVDA   498.14 (+2.17%)
TSLA   448.74 (+1.49%)
BABA   273.33 (+0.34%)
CGC   15.72 (-3.91%)
GE   6.35 (-7.70%)
MU   48.95 (-3.53%)
AMD   77.42 (+3.32%)
T   28.57 (-1.24%)
F   6.84 (-5.39%)
ACB   6.33 (-3.06%)
GILD   64.03 (-1.57%)
NFLX   485.97 (+3.41%)
DIS   125.12 (-2.73%)
BAC   24.38 (-3.29%)
BA   156.41 (-2.94%)
S&P 500   3,281.06 (-1.16%)
DOW   27,147.70 (-1.84%)
QQQ   266.56 (-0.12%)
AAPL   109.36 (+2.36%)
MSFT   201.74 (+0.67%)
FB   248.50 (-1.60%)
GOOGL   1,424.16 (-1.86%)
AMZN   2,942.44 (-0.42%)
NVDA   498.14 (+2.17%)
TSLA   448.74 (+1.49%)
BABA   273.33 (+0.34%)
CGC   15.72 (-3.91%)
GE   6.35 (-7.70%)
MU   48.95 (-3.53%)
AMD   77.42 (+3.32%)
T   28.57 (-1.24%)
F   6.84 (-5.39%)
ACB   6.33 (-3.06%)
GILD   64.03 (-1.57%)
NFLX   485.97 (+3.41%)
DIS   125.12 (-2.73%)
BAC   24.38 (-3.29%)
BA   156.41 (-2.94%)
S&P 500   3,281.06 (-1.16%)
DOW   27,147.70 (-1.84%)
QQQ   266.56 (-0.12%)
AAPL   109.36 (+2.36%)
MSFT   201.74 (+0.67%)
FB   248.50 (-1.60%)
GOOGL   1,424.16 (-1.86%)
AMZN   2,942.44 (-0.42%)
NVDA   498.14 (+2.17%)
TSLA   448.74 (+1.49%)
BABA   273.33 (+0.34%)
CGC   15.72 (-3.91%)
GE   6.35 (-7.70%)
MU   48.95 (-3.53%)
AMD   77.42 (+3.32%)
T   28.57 (-1.24%)
F   6.84 (-5.39%)
ACB   6.33 (-3.06%)
GILD   64.03 (-1.57%)
NFLX   485.97 (+3.41%)
DIS   125.12 (-2.73%)
BAC   24.38 (-3.29%)
BA   156.41 (-2.94%)
S&P 500   3,281.06 (-1.16%)
DOW   27,147.70 (-1.84%)
QQQ   266.56 (-0.12%)
AAPL   109.36 (+2.36%)
MSFT   201.74 (+0.67%)
FB   248.50 (-1.60%)
GOOGL   1,424.16 (-1.86%)
AMZN   2,942.44 (-0.42%)
NVDA   498.14 (+2.17%)
TSLA   448.74 (+1.49%)
BABA   273.33 (+0.34%)
CGC   15.72 (-3.91%)
GE   6.35 (-7.70%)
MU   48.95 (-3.53%)
AMD   77.42 (+3.32%)
T   28.57 (-1.24%)
F   6.84 (-5.39%)
ACB   6.33 (-3.06%)
GILD   64.03 (-1.57%)
NFLX   485.97 (+3.41%)
DIS   125.12 (-2.73%)
BAC   24.38 (-3.29%)
BA   156.41 (-2.94%)
Log in
NASDAQ:CYAD

CELYAD SA/ADR Stock Forecast, Price & News

$9.76
-0.33 (-3.27 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.75
Now: $9.76
$9.95
50-Day Range
$9.70
MA: $10.06
$10.57
52-Week Range
$4.10
Now: $9.76
$13.01
Volume4,629 shs
Average Volume17,716 shs
Market Capitalization$136.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Read More
CELYAD SA/ADR logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYAD
CUSIPN/A
Phone321-039-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Price / Sales13,607.39
Book Value$3.67 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$136.07 million
Next Earnings DateN/A
OptionableNot Optionable
$9.76
-0.33 (-3.27 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYAD News and Ratings via Email

Sign-up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions

How has CELYAD SA/ADR's stock been impacted by COVID-19?

CELYAD SA/ADR's stock was trading at $7.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYAD shares have increased by 24.3% and is now trading at $9.76.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of CELYAD SA/ADR?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CELYAD SA/ADR
.

What price target have analysts set for CYAD?

3 Wall Street analysts have issued twelve-month price targets for CELYAD SA/ADR's shares. Their forecasts range from $20.00 to $37.00. On average, they anticipate CELYAD SA/ADR's stock price to reach $28.50 in the next year. This suggests a possible upside of 192.0% from the stock's current price.
View analysts' price targets for CELYAD SA/ADR
.

Are investors shorting CELYAD SA/ADR?

CELYAD SA/ADR saw a decrease in short interest in August. As of August 31st, there was short interest totaling 6,100 shares, a decrease of 17.6% from the August 15th total of 7,400 shares. Based on an average trading volume of 14,500 shares, the days-to-cover ratio is presently 0.4 days.
View CELYAD SA/ADR's Short Interest
.

Who are some of CELYAD SA/ADR's key competitors?

What other stocks do shareholders of CELYAD SA/ADR own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CELYAD SA/ADR investors own include GALAPAGOS NV/S (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Chromadex (CDXC), SCYNEXIS (SCYX), bluebird bio (BLUE), Ra Pharmaceuticals (RARX), AbbVie (ABBV) and argenx (ARGX).

Who are CELYAD SA/ADR's key executives?

CELYAD SA/ADR's management team includes the following people:
  • Mr. Michel E. Lussier, Co-Founder & Chairman (Age 63)
  • Mr. Filippo Joseph Petti, CEO & Interim CFO
  • Dr. Jean-Pierre Latere, Chief Operating Officer (Age 44)
  • Nicolas Van Hoecke, Director of Investor Relations & Communications
  • Mr. Philippe Dechamps, Chief Legal Officer (Age 49)

When did CELYAD SA/ADR IPO?

(CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

What is CELYAD SA/ADR's stock symbol?

CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD."

Who are CELYAD SA/ADR's major shareholders?

CELYAD SA/ADR's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (5.63%).

Which major investors are selling CELYAD SA/ADR stock?

CYAD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc..

How do I buy shares of CELYAD SA/ADR?

Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CELYAD SA/ADR's stock price today?

One share of CYAD stock can currently be purchased for approximately $9.76.

How big of a company is CELYAD SA/ADR?

CELYAD SA/ADR has a market capitalization of $136.07 million and generates $10,000.00 in revenue each year. The company earns $-32,070,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis.

What is CELYAD SA/ADR's official website?

The official website for CELYAD SA/ADR is www.celyad.com.

How can I contact CELYAD SA/ADR?

CELYAD SA/ADR's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at 321-039-4100.

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.